These posters can find something negative about anything.
I think the interesting point was spending so much time on their advantages including a new advantage relative to the secondary cancer issue recently reported. Helen indicated that it is about CART cells turning cancerous. While I can't speak to hot spots or why activation of CART's outside or inside the body makes a difference, she called out the kill switch (which I previously mentioned as an advantage) as a MAJOR advantage.
Another interesting part was her pointing out that their advantage was even greater when CART's are used to minimize chronic autoimmune diseases like lupus. If true, we have another reason for someone to partner with them on CD-19 CART's to fight lupus. This is just another deal which could come at any time.